USC.edu
Are You a Patient?

Araz Marachelian, MD

Assistant Professor of Clinical Pediatrics

Image of Araz Marachelian, MD
Websites
Is this your profile? Click to edit
Phone +1 323 361 8573
Email [email protected]
CTSI Profile

Awards

  • Undergraduate Research Award National Science Foundation, 1994
  • University of California, Berkeley: Outstanding Service Award, 1995
  • University of California, Berkeley: High Distinction of Honors, 1995
  • University of California, Irvine: Outstanding Achievement in Pediatrics and Psychiatry, 1999
  • AACR/ASCO: Clinical Trial Training Workshop Award, 2005
  • Southern California Super Doctors, 2009
     – 2010
  • Pasadena Magazine: Top Doctor, 2013
  • Southern California Super Doctors, 2014
  • NCI Cancer Clinical Investigator Team Leadership Award (CCITLA), 2014
     – 2015

Publications

  • Impact of Cisplatin-Induced Hearing Loss on Quality of Life in Childhood Cancer Survivors. JCO Oncol Pract. 2026 Jun 22.. View in PubMed
  • Efficacy and Tolerability of Topotecan/Cyclophosphamide/Dinutuximab in Relapsed and Refractory High-Risk Neuroblastoma: A Multi-Institutional Retrospective Study. Pediatr Blood Cancer. 2026 May; 73(5):e70195.. View in PubMed
  • A pilot study of chemoimmunotherapy in the postconsolidation setting for high-risk neuroblastoma (ANBL19P1): A report from the Children’s Oncology Group. Cancer. 2026 Jan 15; 132(2):e70165.. View in PubMed
  • Sequential Combination of Unfavorable Histology, Followed by Clinical Stage M, Defines High-Risk Neuroblastoma: A Report from the Children’s Oncology Group. Clin Cancer Res. 2026 Jan 06; 32(1):127-134.. View in PubMed
  • Phase I Study of 131I-Metaiodobenzylguanidine With Dinutuximab ± Vorinostat for Patients With Relapsed or Refractory Neuroblastoma: A New Approaches to Neuroblastoma Therapy Trial. J Clin Oncol. 2025 08; 43(22):2490-2501.. View in PubMed
  • A phase 1 dose-escalation study of LY3295668 erbumine as monotherapy and in combination with topotecan and cyclophosphamide in children with relapsed/refractory neuroblastoma. Cancer. 2025 Feb 15; 131(4):e35751.. View in PubMed
  • Phase 1 study of high-dose DFMO, celecoxib, cyclophosphamide and topotecan for patients with relapsed neuroblastoma: a New Approaches to Neuroblastoma Therapy trial. Br J Cancer. 2024 03; 130(5):788-797.. View in PubMed
  • Factors influencing parents’ choice of palliative treatment goals for children with relapsed or refractory neuroblastoma: A multi-site longitudinal survey study. Cancer. 2024 04 01; 130(7):1101-1111.. View in PubMed
  • Anti-CCL2 antibody combined with etoposide prolongs survival in a minimal residual disease mouse model of neuroblastoma. Sci Rep. 2023 11 14; 13(1):19915.. View in PubMed
  • Norepinephrine transporter and vesicular monoamine transporter 2 tumor expression as a predictor of response to 131 I-MIBG in patients with relapsed/refractory neuroblastoma. Pediatr Blood Cancer. 2024 Jan; 71(1):e30743.. View in PubMed

Similar People